Literature DB >> 26077553

Risk factors for primary sclerosing cholangitis.

Kirsten Boonstra1, Elisabeth M G de Vries1, Nan van Geloven2, Karel J van Erpecum3, Marcel Spanier4, Alexander C Poen5, Carin M van Nieuwkerk6, Ben J Witteman7, Hans A Tuynman8, Anton H Naber9, Paul J Kingma9, Ulrich Beuers1, Cyriel Y Ponsioen1.   

Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease of unknown cause, but strongly associated with inflammatory bowel disease (IBD). Potential risk factors triggering PSC have never been studied on a population level. The aim of this study was to evaluate smoking, appendectomy, family history and geographical distribution in a population-based cohort of PSC patients, as compared to IBD control patients and healthy controls (HC).
METHODS: For this case-control study 343 PSC patients, 370 IBD controls and 232 HC's living in a geographically defined area in the Netherlands filled-out a questionnaire concerning smoking, appendectomy and family history of IBD and autoimmune liver diseases.
RESULTS: Smoking was associated with a lower risk of developing PSC in PSC-ulcerative colitis (UC) patients (adjusted OR 0.21; 95% CI 0.12-0.34; P < 0.001). Comparable results were found for PSC-Crohn's disease (CD) patients (16% former smokers) compared to CD patients (55% former smokers) (adjusted OR 0.17; 95% CI 0.08-0.39; P < 0.001). Frequency of appendectomy did not differ between PSC and HC, but PSC-UC patients had undergone appendectomy more often than UC patients (13% vs. 6%) (adjusted OR 2.51; 95%CI 1.04-6.07; P = 0.041). We found no association between family history of IBD or autoimmune liver disease and risk of PSC. Degree of urbanization was not associated with PSC incidence.
CONCLUSION: In this large population-based case-control study we confirm that smoking is associated with a lower risk of developing PSC, independent of its protective effect for developing UC. Appendectomy is not associated with the risk of developing PSC.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  appendectomy; primary sclerosing cholangitis; risk factors; smoking

Mesh:

Year:  2015        PMID: 26077553     DOI: 10.1111/liv.12894

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Association between smoking and risk of primary sclerosing cholangitis: A systematic review and meta-analysis.

Authors:  Karn Wijarnpreecha; Panadeekarn Panjawatanan; Omar Y Mousa; Wisit Cheungpasitporn; Surakit Pungpapong; Patompong Ungprasert
Journal:  United European Gastroenterol J       Date:  2018-02-21       Impact factor: 4.623

2.  National incidence of autoimmune liver diseases and its relationship with the human development index.

Authors:  Hong-Ying Pan; Yi-Ning Dai; Ji-Na Zheng; Ke-Qing Shi; Sven Van Poucke; Hai Zou; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-07-19

Review 3.  Review of primary sclerosing cholangitis with increased IgG4 levels.

Authors:  Charis D Manganis; Roger W Chapman; Emma L Culver
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

4.  Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies.

Authors:  Dagfinn Aune; Abhijit Sen; Teresa Norat; Elio Riboli; Trine Folseraas
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.379

5.  Gene Set Enrichment Analysis Detected Immune Cell-Related Pathways Associated with Primary Sclerosing Cholangitis.

Authors:  Pan Luo; Lin Liu; Weikun Hou; Ke Xu; Peng Xu
Journal:  Biomed Res Int       Date:  2022-08-26       Impact factor: 3.246

6.  Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis.

Authors:  Nelli Sjöblom; Sonja Boyd; Hannu Kautiainen; Johanna Arola; Martti Färkkilä
Journal:  Histopathology       Date:  2022-05-31       Impact factor: 7.778

7.  Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.

Authors:  Bertus Eksteen; Christopher L Bowlus; Aldo J Montano-Loza; Eric Lefebvre; Laurent Fischer; Pamela Vig; Eduardo Bruno Martins; Jawad Ahmad; Kidist K Yimam; Paul J Pockros; Jordan J Feld; Gerald Minuk; Cynthia Levy
Journal:  Hepatol Commun       Date:  2020-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.